Last reviewed · How we verify
GSK2110183 Gelatin Capsule
At a glance
| Generic name | GSK2110183 Gelatin Capsule |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Bioavailability and Food Effect of the Original Gelatin Formulation and Two New Formulations of Afuresertib in Normal Healthy Volunteers (PHASE1)
- Bioavailability and Food Effect Study of Gelatin Formulation and Immediate Release Tablet Formulation of Afuresertib (PHASE1)
- A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK2110183 Gelatin Capsule CI brief — competitive landscape report
- GSK2110183 Gelatin Capsule updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI